SCHEMBL28883121

SCHEMBL28883121

CC(O)CN1CCCNCC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.50
CXCR4 P61073 9/20 0.47
CHRM5 P08912 1/20 0.44
CHRM3 P20309 1/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
ADRA2C P18825 1/20 0.42
CCR2 P41597 1/20 0.42
CXCL12 P48061 1/20 0.42
BLM P54132 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
SIGMAR1 Q99720 1/20 0.39
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
RAD52 P43351 1/20 0.37
IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28888023 0.96 CXCR4 (0.53) SMN1; SMN2CXCR4CHRM5CHRM3MEN1
SCHEMBL4904768 0.94 SMN1; SMN2 (0.49) SMN1; SMN2CXCR4CHRM5CHRM3MEN1
SCHEMBL154268 0.92 SMN1; SMN2 (0.56) SMN1; SMN2CHRM5CHRM3MEN1KMT2A
SCHEMBL13833167 0.92 SMN1; SMN2 (0.56) SMN1; SMN2CHRM5CHRM3MEN1KMT2A
SCHEMBL1974799 0.92 SMN1; SMN2 (0.56) SMN1; SMN2CHRM5CHRM3MEN1KMT2A
SCHEMBL1393824 0.92 SMN1; SMN2 (0.56) SMN1; SMN2CHRM5CHRM3MEN1KMT2A
SCHEMBL10667505 0.92 SMN1; SMN2 (0.56) SMN1; SMN2CHRM5CHRM3MEN1KMT2A
SCHEMBL3422751 0.90 SMN1; SMN2 (0.55) SMN1; SMN2CXCR4CHRM5CHRM3MEN1
SCHEMBL20565492 0.90 SMN1; SMN2 (0.55) SMN1; SMN2CHRM5CHRM3MAPTRAD52
SCHEMBL22014102 0.90 SMN1; SMN2 (0.55) SMN1; SMN2CHRM5CHRM3MAPTRAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109153934-B Polyester dispersants, synthesis and uses thereof 雪佛龙奥伦耐有限责任公司 2022-04-05 CN claimed
US-20240293364-A1 BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-09-05 US disclosed
US-20230338337-A1 BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 US disclosed
US-20230313313-A1 BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-10-05 US disclosed
CN-109153934-B Polyester dispersants, synthesis and uses thereof 雪佛龙奥伦耐有限责任公司 2022-04-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293364-A1 BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS MSH2, MRE11, RAD50 SMN1; SMN2 3064/4885CXCR4 2124/4885CHRM5 4788/4885
US-20230313313-A1 BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS SKP2, MDM2, TP53 SMN1; SMN2 3472/4885CXCR4 2814/4885CHRM5 4849/4885
US-20230338337-A1 BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS IRF2BP2, BST2, IRF3 SMN1; SMN2 3980/4885CXCR4 1408/4885CHRM5 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.